Stockscreener 앱 받기
163.33
2.99%
-5.04
시장 영업 전:
163.78
0.45
+0.28%
Astrazeneca Plc 주식(AZN)의 최신 뉴스
AstraZeneca stock heads into the open after a 2.84 percent drop - AD HOC NEWS
AstraZeneca stock heads into the open after a 1.20 percent drop - AD HOC NEWS
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026 - GlobeNewswire Inc.
AstraZeneca stock falls 2.65 percent after the close - AD HOC NEWS
AstraZeneca wins EU label expansion for Trixeo in asthma (AZN) - Seeking Alpha
AstraZeneca's Trixeo Secures Approval for Asthma in the EU - Yahoo Finance Australia
AstraZeneca LSE:AZN EU Drug Wins Put Cancer and Autoimmune Growth in Focus - kalkinemedia.com
AstraZeneca stock slips as Trixeo wins EU asthma approval - AD HOC NEWS
EU clears first triple-therapy asthma medicine from AstraZeneca (AZN) - stocktitan.net
AstraZeneca (LSE:AZN) Pipeline Wins Put Valuation in Focus - Kalkine Media
AstraZeneca wins EU approval for Trixeo asthma inhaler - proactiveinvestors.co.uk
AstraZeneca PLC Announces Trixeo Approved In EU For Asthma - TradingView
AstraZeneca’s Trixeo Aerosphere Approved In EU For Asthma - DirectorsTalk Interviews
REGAstraZeneca PLCTrixeo approved in EU for asthma - TradingView
AstraZeneca stock heads into the open after a 0.08 percent fall - AD HOC NEWS
AstraZeneca stock gains 1.22 percent at the close - AD HOC NEWS
BreakingviewsCOMMENTARY: Big Pharma growth malady has a risky cure - Reuters
AstraZeneca stock gains as Deutsche Bank raises its target - AD HOC NEWS
AZN Historical Stock Prices & Daily Price Data | AstraZeneca PLC - Quiver Quantitative
AstraZeneca and Daiichi Sankyo’s Breast Cancer Drug Approved for NHS Use in England - Insider Monkey
AstraZeneca PLC (AZN) Stock Analysis: Is A 27.75% Upside On The Horizon? - DirectorsTalk Interviews
Two favorable EU opinions for AstraZeneca - marketscreener.com
AstraZeneca’s Klygefa Recommended For EU Approval In Generalised Myasthenia Gravis - DirectorsTalk Interviews
AstraZeneca PLC (AZN.L) Stock Analysis: Unveiling a 26% Upside Potential Amid Strong Buy Ratings - DirectorsTalk Interviews
AstraZeneca PLC (Dinari Tokenized Stock)AZNStock Price & News - The Motley Fool
AstraZeneca PLC Agencies, 2024 - OpenSecrets
Long Wait Is Good Omen For AstraZeneca’s AVANZAR Lung Cancer Trial - insights.citeline.com
AstraZeneca, Daiichi Sankyo's Enhertu Recommended for EU Approval for HER2 Positive Breast Cancer - marketscreener.com
AstraZeneca (AZN) CEO buys 60,000 shares in LON trade - stocktitan.net
FDA Grants Priority Review to AstraZeneca's Efzimfotase - marketscreener.com
AstraZeneca Wins FDA Priority Review for Rare Bone Disease Drug - marketscreener.com
Enhertu recommended for approval in the EU by CHMP as adjuvant treatment for patients with residual disease after neoadjuvant treatment for HER2-positive early breast cancer - astrazeneca.com
AstraZeneca Wins US FDA Priority Review for Hypophosphatasia Therapy - marketscreener.com
AstraZeneca (AZN)’s Lung Drug Delivers the Good News its Pipeline Needed - Yahoo Finance
AstraZeneca advances Thursday, outperforms market - MarketWatch
AstraZeneca (AZN) Wins FDA Approval for its Breast Cancer Pill After Regulators Voiced Doubts - Yahoo Finance
AstraZeneca-Daiichi breast cancer drug cleared for NHS use in England - Reuters
Enhertu Approved by NICE for NHS, Impact on AstraZeneca (AZN) Un - gurufocus.com
Key facts: AstraZeneca PLC wins NHS access for breast cancer; pipeline could yield $10B - TradingView
AstraZeneca Shares Rise as J.P. Morgan Stays Overweight - Yahoo Finance
AstraZeneca shares oversold after trial flops and merger talk, says UBS - Proactive financial news
AstraZeneca's news flow next year could sustain drugs group beyond 2030, says leading bank - Yahoo! Finance Canada
AstraZeneca PLC : Gets a Buy rating from UBS - marketscreener.com
AstraZeneca PLC : JP Morgan keeps its Buy rating - marketscreener.com
Dividend-linked share awards boost AstraZeneca (NYSE: AZN) CFO stake - stocktitan.net
AstraZeneca’s Oncology Engine Faces a Key Test After Camizestrant Miss - Yahoo Finance
AstraZeneca (AZN) chair buys 2,500 shares on LON - Stock Titan
AstraZeneca PLC Lobbyists, 2013 - OpenSecrets
AstraZeneca breast cancer drug fails trial but Citi keeps 'buy' rating - Yahoo Finance
AstraZeneca (AZN) says breast cancer trial fell short - stocktitan.net
AstraZeneca stock holds steady amid licensing deal for novel Lp(a) inhibitor - ad-hoc-news.de
AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears - Yahoo Finance
AstraZeneca stock falls as Etcamah trial setback clouds oncology outlook - ad-hoc-news.de
AstraZeneca: The $5 Billion Pipeline Hole Did Not Stay Open Long (NYSE:AZN) - Seeking Alpha
AstraZeneca breast cancer drug fails late-stage trial goal By Investing.com - Investing.com Nigeria
AstraZeneca's breast cancer pill fails in late-stage trial - Reuters
AstraZeneca's Etcamah fails in late-stage trial as first-line breast cancer treatment - Seeking Alpha
AstraZeneca stock falls after Etcamah trial setback despite strong oncology pipeline - ad-hoc-news.de
AstraZeneca Says Late-Stage Etcamah Breast-Cancer Trial Misses Main Goal - marketscreener.com
AstraZeneca breast cancer drug fails late-stage trial goal - investing.com
AstraZeneca Says Breast Cancer Pill Fails in Key Study - Bloomberg.com
AstraZeneca : Update on SERENA-4 Phase III trial of Etcamah in combination with palbociclib in upfront 1st-line advanced ER-positive breast cancer - marketscreener.com
Update on SERENA-4 Phase III trial of Etcamah in combination with palbociclib in upfront 1st-line advanced ER-positive breast cancer - AstraZeneca
Jim Cramer Says He Is Not Going to Put His Money on AstraZeneca (AZN) - Yahoo Finance
AstraZeneca Halts Early Lung Cancer Imaging Trial: What Investors Should Watch Next - TipRanks
Positive Lung Cancer Data Lifts the Case for Amgen and AstraZeneca - Yahoo Finance
1.01%
1.01%
자본화:
|
볼륨(24시간):